Baker McKenzie Advises Servier on the Acquisition of Day One Biopharmaceuticals for Approximately USD 2.5 Billion

Baker McKenzie is representing Servier, an independent international pharmaceutical group governed by a foundation, on its definitive agreement to acquire Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a commercial stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with life threatening diseases, for approximately USD 2.5 billion.
Under the terms of the merger agreement, Servier will commence a cash tender offer to acquire all of the issued and outstanding shares of Day One’s common stock for $21.50 per share in cash. Upon the successful completion of the tender offer, Servier will acquire any shares not acquired in the tender through a second-step merger for the same consideration per share paid in the tender offer. Subject to customary closing conditions, the deal is expected to close in the second quarter of 2026.
The acquisition strengthens Servier’s oncology portfolio and expands its pipeline with programs targeting adult and pediatric cancers with high unmet medical needs, reinforcing Servier’s ambition to become a leading innovator in oncology.